Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 11/20 | 0.51 |
| ▸ | MMP3 | P08254 | 3/20 | 0.50 |
| ▸ | MMP2 | P08253 | 3/20 | 0.50 |
| ▸ | MMP9 | P14780 | 2/20 | 0.50 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.49 |
| ▸ | MMP7 | P09237 | 1/20 | 0.48 |
| ▸ | MMP8 | P22894 | 1/20 | 0.48 |
| ▸ | MMP13 | P45452 | 1/20 | 0.48 |
| ▸ | LDHA | P00338 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31530464 | 0.85 | ACACB (0.46) | MMP1MMP3 | |
| SCHEMBL18603572 | 0.84 | ALDH1A1 (0.61) | MMP1MMP3MMP9 | |
| SCHEMBL13033619 | 0.84 | LDHA (0.57) | MMP1MMP3MMP2MMP9LDHA | |
| SCHEMBL8645164 | 0.84 | LDHA (0.57) | MMP1MMP3MMP2MMP9LDHA | |
| SCHEMBL12706395 | 0.83 | CTSS (0.52) | MMP1 | |
| SCHEMBL7933561 | 0.82 | MMP1 (0.49) | MMP1MMP13LDHA | |
| Bromide SCHEMBL28191668 | 0.81 | LDHA (0.54) | MMP1MMP3MMP2MMP9ADAM17 | |
| SCHEMBL15223323 | 0.80 | LDHA (0.45) | LDHA | |
| SCHEMBL18603730 | 0.80 | FPR2 (0.65) | MMP1MMP3MMP9LDHA | |
| SCHEMBL18603732 | 0.80 | FPR2 (0.65) | MMP1MMP3MMP9LDHA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170218025-A1 | BOUVARDIN DERIVATIVES AND THERAPEUTIC USES THEREOF | SUVICA, INC. | 2017-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170218025-A1 | BOUVARDIN DERIVATIVES AND THERAPEUTIC USES THEREOF | EIF4E, EIF4EBP1, RPL30 | MMP1 4343/4885MMP3 2096/4885MMP2 2452/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.